These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31622242)

  • 1. Dynamics of soluble syndecan-1 in maternal serum during and after pregnancies complicated by preeclampsia: a nested case control study.
    Kuessel L; Husslein H; Montanari E; Kundi M; Himmler G; Binder J; Schiefer J; Zeisler H
    Clin Chem Lab Med; 2019 Dec; 58(1):50-58. PubMed ID: 31622242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of syndecan-1 and hyaluronan in early- and late-onset preeclampsia.
    Kornacki J; Wirstlein P; Wender-Ozegowska E
    Pregnancy Hypertens; 2019 Oct; 18():108-111. PubMed ID: 31586782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of CYFRA 21-1 to diagnose and predict preeclampsia: a nested case-control study.
    Kuessel L; Zeisler H; Ristl R; Binder J; Pateisky P; Schmid M; Marschalek J; Perkmann T; Haslacher H; Husslein H
    BMC Pregnancy Childbirth; 2016 Nov; 16(1):339. PubMed ID: 27809797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamics of serum C-type natriuretic peptide as predictor for preeclampsia.
    Kuessel L; Zeisler H; Himmler G; Kundi M; Montanari E; Binder J; Husslein H; Marschalek J; Ott J
    Pregnancy Hypertens; 2018 Oct; 14():286-292. PubMed ID: 29472019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of maternal serum hypoxia inducible factor-1α, progranulin and syndecan-1 levels in pregnancies with early- and late-onset preeclampsia.
    Alici Davutoğlu E; Akkaya Firat A; Ozel A; Yılmaz N; Uzun I; Temel Yuksel I; Madazlı R
    J Matern Fetal Neonatal Med; 2018 Aug; 31(15):1976-1982. PubMed ID: 28574293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Soluble Syndecan-1 Precedes Preeclampsia.
    Gandley RE; Althouse A; Jeyabalan A; Bregand-White JM; McGonigal S; Myerski AC; Gallaher M; Powers RW; Hubel CA
    PLoS One; 2016; 11(6):e0157608. PubMed ID: 27299886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in women with preeclampsia.
    Garg P; Jaryal AK; Kachhawa G; Deepak KK; Kriplani A
    Pregnancy Hypertens; 2018 Oct; 14():245-251. PubMed ID: 29548740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Syndecan-1 as a Novel Biomarker for Adverse Pregnancy Outcomes.
    Greeley ET; Rochelson B; Krantz DA; Xue X; Carmichael JB; Ashour S; Woo S; Augustine S; Metz CN
    Reprod Sci; 2020 Jan; 27(1):355-363. PubMed ID: 32046458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Level of Placenta-Derived Macrophage-Stimulating Protein -Chain in Preeclampsia before 20 Weeks of Pregnancy.
    Zhang Y; Yang H; Long Y; Ma Q; Chen R
    PLoS One; 2016; 11(8):e0161626. PubMed ID: 27559727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal Serum Angiogenic Factor sFlt-1 to PlGF Ratio in Preeclampsia: A Useful Marker for Differential Diagnosis and Prognosis Evaluation in Chinese Women.
    Lou WZ; Jiang F; Hu J; Chen XX; Song YN; Zhou XY; Liu JT; Bian XM; Gao JS
    Dis Markers; 2019; 2019():6270187. PubMed ID: 31396294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia.
    Bian Z; Shixia C; Duan T
    PLoS One; 2015; 10(4):e0124684. PubMed ID: 25906026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies.
    Dröge L; Herraìz I; Zeisler H; Schlembach D; Stepan H; Küssel L; Henrich W; Galindo A; Verlohren S
    Ultrasound Obstet Gynecol; 2015 Mar; 45(3):286-93. PubMed ID: 25491901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy.
    Birdir C; Droste L; Fox L; Frank M; Fryze J; Enekwe A; Köninger A; Kimmig R; Schmidt B; Gellhaus A
    Pregnancy Hypertens; 2018 Apr; 12():124-128. PubMed ID: 29674192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of serum human pregnancy-specific beta-1-glycoprotein 1 levels in pregnant women with or without preeclampsia.
    Temur M; Serpim G; Tuzluoğlu S; Taşgöz FN; Şahin E; Üstünyurt E
    J Obstet Gynaecol; 2020 Nov; 40(8):1074-1078. PubMed ID: 31790616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome.
    Muñoz-Hernández R; Medrano-Campillo P; Miranda ML; Macher HC; Praena-Fernández JM; Vallejo-Vaz AJ; Dominguez-Simeon MJ; Moreno-Luna R; Stiefel P
    Am J Hypertens; 2017 Jul; 30(7):673-682. PubMed ID: 28338787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies.
    Saleh L; Tahitu SIM; Danser AHJ; van den Meiracker AH; Visser W
    Pregnancy Hypertens; 2018 Oct; 14():222-227. PubMed ID: 29678353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revised competing-risks model in screening for pre-eclampsia in twin pregnancy by maternal characteristics and medical history.
    Benkő Z; Chaveeva P; de Paco Matallana C; Zingler E; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Nov; 54(5):617-624. PubMed ID: 31364214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble syndecan-1 and glycosaminoglycans in preeclamptic and normotensive pregnancies.
    Hassani Lahsinoui H; Amraoui F; Spijkers LJA; Veenboer GJM; Peters SLM; van Vlies N; Vogt L; Ris-Stalpers C; van den Born BJH; Afink GB
    Sci Rep; 2021 Feb; 11(1):4387. PubMed ID: 33623064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.